Skip to content

Physician-led care since 20194.9 on Google

Text (407) 233-4006Call

Not sure where to start? Answer a few questions about your symptoms in the 4-minute hormone quiz.

Take the quiz

Not near a clinic? Peptide therapy is available by telehealth in 27 states.Telehealth

Your care team

  • Dr. Joseph Clark, D.O.

    Dr. Joseph Clark, D.O.

    Chief Medical Officer

    Board certified in Emergency Medicine, with 20+ years in medicine.

  • Tomo Marjanovic

    Tomo Marjanovic

    Founder and CEO

    Former police officer awarded the Medal of Valor. IFAH Top 100 Healthcare Visionary.

4.9 on Google from 700+ reviews

Aspire Rejuvenation Clinic

Menu

Text or call us at (407) 233-4006. Mon to Fri, 9:30 AM to 6:00 PM.

Book a Consultation

Peptide Therapy  /  LL-37

LL-37

LL-37 is the only human cathelicidin antimicrobial peptide, a 37-amino acid peptide that serves as a critical component of the innate immune system. Beyond its direct antimicrobial activity against bacteria, viruses, and fungi, LL-37 functions as an immunomodulatory signaling molecule that bridges innate and adaptive immunity.

ClassificationCathelicidin Antimicrobial Peptide
Sequence Length37 Amino Acids
Primary InterestAntimicrobial Defense & Immune Modulation
Research StatusExtensive Research (Preclinical + Clinical Observations)
Interested in LL-37?

Talk with an Aspire clinician about whether LL-37 may be appropriate for your health goals.

Text Us Now
(407) 233-4006
What is LL-37?

The Human Cathelicidin - Innate Immune Defense Peptide

LL-37 (beginning with two leucine residues, hence the name) is the sole member of the cathelicidin family of antimicrobial peptides in humans. It is produced by cleavage of the precursor protein hCAP-18 (human cationic antimicrobial protein 18 kDa) by the serine protease proteinase 3. LL-37 is expressed by neutrophils, macrophages, epithelial cells of the skin, airways, and gastrointestinal tract, and is also found in wound fluid, sweat, and breast milk. It represents a first line of defense in the body's innate immune response.

Research has revealed that LL-37's biological roles extend far beyond simple microbial killing. It serves as a chemokine, attracting immune cells to sites of infection and injury. It modulates inflammatory responses, promotes angiogenesis (new blood vessel formation), and stimulates wound healing. It neutralizes bacterial endotoxins (LPS), modulates dendritic cell differentiation, and influences adaptive immune responses. Studies have also identified anti-biofilm activity, making it relevant to chronic infections where biofilm formation limits the effectiveness of conventional antibiotics. LL-37 deficiency has been associated with increased susceptibility to infections in various clinical contexts.

Aspire Rejuvenation offers LL-37 through licensed 503A compounding pharmacies for patients with recurrent infections, chronic infectious conditions, immune support needs, or wound healing concerns. Our physicians evaluate each patient's immune status, infection history, and specific clinical situation to determine whether LL-37's unique antimicrobial and immunomodulatory properties are appropriate for their needs.

Lifestyle photography representing running woman fitness - LL-37 therapy at Aspire Rejuvenation
How It Works

Proposed Mechanism of Action

1
Membrane Disruption
LL-37's cationic (positively charged) amphipathic alpha-helical structure allows it to bind to and disrupt negatively charged microbial membranes, creating pores that kill bacteria, enveloped viruses, and fungi through direct lysis.
2
Immune Cell Recruitment
LL-37 acts as a chemokine, attracting neutrophils, monocytes, and T-cells to sites of infection through formyl peptide receptor-like 1 (FPRL1) activation, amplifying the local immune response.
3
Biofilm Disruption
Research has demonstrated LL-37's ability to prevent biofilm formation and disrupt established biofilms from organisms including Pseudomonas aeruginosa and Staphylococcus species, addressing a major limitation of conventional antibiotic therapy.
4
Wound Healing Promotion
LL-37 promotes wound healing through multiple mechanisms: stimulating epithelial cell migration, promoting angiogenesis via VEGF-like activity, and modulating the inflammatory-to-regenerative transition at wound sites.

LL-37's antimicrobial mechanism relies on its physical and chemical properties. As a cationic amphipathic peptide, it adopts an alpha-helical conformation in the presence of biological membranes. The positively charged face of the helix is attracted to the negatively charged lipopolysaccharides (LPS) and lipoteichoic acids on bacterial membranes - structures not found on mammalian cell membranes (which have neutral phospholipids on their outer leaflet). This electrostatic selectivity allows LL-37 to preferentially target microbial membranes. Upon binding, LL-37 inserts into the lipid bilayer and creates pores through a carpet-like or toroidal pore mechanism, disrupting membrane integrity and causing cell death. This physical mechanism of action makes it difficult for bacteria to develop resistance, unlike conventional antibiotics.

LL-37's immunomodulatory functions are equally important and operate through defined receptor systems. Binding to FPRL1 (formyl peptide receptor-like 1) on immune cells triggers chemotaxis, bringing additional immune defenders to infection sites. Through P2X7 receptor activation, LL-37 can induce IL-1beta release from macrophages, bridging innate and adaptive immunity. It also activates toll-like receptor (TLR) signaling pathways that enhance pathogen recognition. In wound healing contexts, LL-37 promotes keratinocyte and fibroblast migration through EGFR transactivation, stimulates angiogenesis by acting on endothelial cells, and modulates the inflammatory phase of healing to support the transition to proliferative repair. Additionally, LL-37 directly neutralizes bacterial LPS (endotoxin), which can reduce the systemic inflammatory response to bacterial infections.

Areas of Interest

What LL-37 Is Being Explored For

These are the primary areas where LL-37 has been studied or discussed in the context of peptide therapy. Research depth varies by area.

Recurrent & Chronic Infections
LL-37's broad-spectrum antimicrobial activity and ability to disrupt biofilms make it a subject of research for recurrent or chronic infections that resist conventional antibiotic treatment, including those involving biofilm-forming organisms.
Immune System Support
As an endogenous immune peptide, LL-37 has been studied for its role in supporting innate immune function. Research has examined whether exogenous LL-37 can enhance immune defense in individuals with suboptimal LL-37 expression or increased infectious challenge.
Wound Healing & Tissue Repair
LL-37's dual role in antimicrobial defense and wound healing promotion makes it particularly relevant for wounds with infection risk. Research has demonstrated enhanced re-epithelialization, angiogenesis, and reduced bacterial colonization in wound models.
Respiratory Health
LL-37 is naturally expressed in airway epithelial cells and is a key component of respiratory innate defense. Research has examined its role in respiratory infections and its potential as a support therapy for respiratory immune challenges.
Available at Aspire

How LL-37 Is Offered

LL-37 is available through Aspire in the following formulations, all compounded by licensed U.S. 503A pharmacies. Your clinician will recommend the appropriate form based on your goals and treatment plan.

Injectable (Subcutaneous)
Questions About LL-37?

Text our team anytime during business hours.
Monday through Friday, 9:30 AM - 6:00 PM.
We're here to help you understand your options.

Text Us Now — (407) 233-4006
The Aspire Approach

How Treatment Works

Peptide therapy at Aspire follows a clinician-guided process. LL-37 is not available for self-prescribing or anonymous purchase.

1
Immune & Infection Assessment
Your evaluation includes immune markers, infection history, vitamin D status (which regulates LL-37 expression), and any current infectious concerns to establish the clinical context for LL-37 consideration.
2
Clinical Indication Review
An Aspire physician evaluates whether LL-37's specific properties - antimicrobial, anti-biofilm, immunomodulatory, or wound healing - align with your clinical needs, and how it may complement other therapeutic approaches.
3
Pharmacy Preparation
Your LL-37 is prepared by a licensed 503A compounding pharmacy with verified purity. Our clinical team provides detailed administration guidance specific to your indication and treatment goals.
4
Response Assessment
Follow-up appointments evaluate clinical response, monitor immune markers, and assess infection status. Your physician adjusts the LL-37 protocol based on your clinical trajectory and ongoing needs.
Frequently Asked Questions

LL-37 FAQ

LL-37 has demonstrated broad-spectrum activity in research. It has been shown effective against gram-positive bacteria (including Staphylococcus aureus and MRSA), gram-negative bacteria (including Pseudomonas aeruginosa and E. coli), enveloped viruses, and fungi (including Candida species). Its physical membrane-disruption mechanism provides activity against organisms that may be resistant to conventional antibiotics.
LL-37 kills microbes by physically disrupting their membranes, which is fundamentally different from antibiotics that target specific metabolic pathways or structures. This physical mechanism makes it very difficult for bacteria to develop resistance. Additionally, LL-37 simultaneously recruits immune cells, modulates inflammation, disrupts biofilms, and promotes wound healing - multifunctional properties that antibiotics do not possess.
Resistance to membrane-disrupting antimicrobial peptides like LL-37 is much more difficult to develop than resistance to conventional antibiotics, because it would require fundamental changes to microbial membrane composition. While some bacteria have evolved partial resistance mechanisms, the physical nature of LL-37's action makes widespread resistance unlikely compared to conventional antibiotics.
Vitamin D is a primary regulator of LL-37 expression. When vitamin D binds to its receptor in immune cells, it directly activates transcription of the gene encoding hCAP-18 (LL-37's precursor). Vitamin D deficiency is associated with reduced LL-37 levels and increased infection susceptibility. This is why Aspire checks vitamin D status as part of the LL-37 evaluation.
Biofilms are structured communities of bacteria encased in a protective matrix that makes them up to 1,000 times more resistant to antibiotics than free-floating bacteria. They are responsible for many chronic and recurrent infections. LL-37's demonstrated ability to both prevent biofilm formation and disrupt established biofilms represents a significant advantage in addressing these challenging infections.
LL-37 achieves selectivity because mammalian cell membranes have a different lipid composition than microbial membranes. The outer leaflet of human cell membranes is composed primarily of neutral phospholipids, which have lower affinity for the positively charged LL-37 compared to the negatively charged microbial membranes. At therapeutic concentrations, LL-37 preferentially targets microbial membranes.
LL-37 is not positioned as a replacement for antibiotics but rather as a complementary approach, particularly in situations involving biofilm-related infections, antibiotic-resistant organisms, or immune support needs. Your Aspire physician evaluates whether LL-37 is appropriate alongside, or as an adjunct to, conventional antimicrobial treatment.
LL-37 may be considered for individuals with recurrent infections, chronic infections involving biofilm-forming organisms, suboptimal innate immune function, wound healing challenges with infection risk, or those seeking immune system support during periods of increased infectious challenge. A thorough evaluation by an Aspire physician determines individual appropriateness.

LL-37 is one of the most extensively studied antimicrobial peptides in the literature, with thousands of published papers characterizing its antimicrobial, immunomodulatory, and wound healing properties. Clinical application is growing as understanding of its roles in human immunity continues to expand.

Ready to explore LL-37?

Talk with an Aspire clinician about your goals and whether LL-37 therapy may be appropriate for you.

Text Us Now
(407) 233-4006  ·  8014 Via Dellagio Way #104, Orlando, FL 32819
ASPIRE CLINIC LOCATIONS

Speak With Our Experts